| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstracts Index
|
|
|
2002
|
5 |
6 |
p. 599-605
7 p.
|
artikel
|
| 2 |
Author Index, Volume 5
|
|
|
2002
|
5 |
6 |
p. 606-
1 p.
|
artikel
|
| 3 |
CC1 LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES: UPDATED RESULTS
|
Conway, K
|
|
2002
|
5 |
6 |
p. 459-
1 p.
|
artikel
|
| 4 |
CC3 MEASURING POPULATION HEALTH FOR 191 COUNTRIES:WHO METHODS AND RESULTS
|
Mathers, CD
|
|
2002
|
5 |
6 |
p. 460-
1 p.
|
artikel
|
| 5 |
CC2 RECOMMENDATIONS ON HRQL/UTILITY DATA IN 14 EUROPEAN PHARMACOECONOMIC GUIDELINES
|
Szende, A
|
|
2002
|
5 |
6 |
p. 460-
1 p.
|
artikel
|
| 6 |
CN1 A STOCHASTIC ECONOMIC EVALUATION OF LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY
|
Fricke, FU
|
|
2002
|
5 |
6 |
p. 443-
1 p.
|
artikel
|
| 7 |
CN2 ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
|
Neymark, N
|
|
2002
|
5 |
6 |
p. 443-444
2 p.
|
artikel
|
| 8 |
CN3 IMMUNOTHERAPY WITH AUTOLOGOUS TUMOR CELL-BCG VACCINE (ONCOVAX®) IN PATIENTS WITH STAGE II COLON CANCER: MEDICAL AND ECONOMIC BENEFITS
|
Uyl-de Groot, CA
|
|
2002
|
5 |
6 |
p. 444-
1 p.
|
artikel
|
| 9 |
CP3 CLAIMS BASED MEASURES OF DRUG TAKING COMPLIANCE AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA: FEASIBILITY AND PREDICTIVE UTILITY
|
Christensen, DB
|
|
2002
|
5 |
6 |
p. 451-452
2 p.
|
artikel
|
| 10 |
CP1 CROSS-CULTURAL DIFFERENCES IN NONADHERENT ATTITUDES
|
Bolge, SC
|
|
2002
|
5 |
6 |
p. 450-451
2 p.
|
artikel
|
| 11 |
CP2 THE IMPACT OF VARYING DEGREES OF COMPLIANCE WITH OSTEOPOROSIS MEDICATION ON FRACTURE RATES IN ACTUAL PRACTICE
|
Caro, JJ
|
|
2002
|
5 |
6 |
p. 451-
1 p.
|
artikel
|
| 12 |
CV1 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN AS PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY
|
Posnett, J
|
|
2002
|
5 |
6 |
p. 444-
1 p.
|
artikel
|
| 13 |
CV2 ESTIMATION OF EXPENDITURES FOR CORONARY HEART DISEASE (CHD) IN GERMANY
|
Wendland, G
|
|
2002
|
5 |
6 |
p. 444-445
2 p.
|
artikel
|
| 14 |
CV3 MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE
|
Mullins, CD
|
|
2002
|
5 |
6 |
p. 445-
1 p.
|
artikel
|
| 15 |
DISCLOSURE INFORMATION
|
|
|
2002
|
5 |
6 |
p. 591-598
8 p.
|
artikel
|
| 16 |
HP3 A RISK-ADJUSTED LEAGUE TABLE OF EXPECTED RETURNS
|
Sendi, P
|
|
2002
|
5 |
6 |
p. 450-
1 p.
|
artikel
|
| 17 |
HP1 EFFICIENT PRODUCTION OF HEALTH BENEFITS: COST-EFFECTIVENESS EVIDENCE AND UTILISATION OF HEALTH TECHNOLOGY IN THE UK
|
Benedict, Á
|
|
2002
|
5 |
6 |
p. 449-450
2 p.
|
artikel
|
| 18 |
HP2 HEALTH ECONOMIC EDUCATION IN ALLOCATION DECISIONS:A PRE-TEST POST-TEST STUDY
|
Evans, CJ
|
|
2002
|
5 |
6 |
p. 450-
1 p.
|
artikel
|
| 19 |
HS1 COST-EFFECTIVENESS AND BUDGET IMPACT OF THE SIROLIMUS-ELUTING STENT IN THE STENT ERA
|
Marchetti, M
|
|
2002
|
5 |
6 |
p. 457-
1 p.
|
artikel
|
| 20 |
HS2 COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR CARDIAC SURGERY
|
Van Hulst, M
|
|
2002
|
5 |
6 |
p. 457-
1 p.
|
artikel
|
| 21 |
HS3 ECONOMIES OF SCALE IN INTENSIVE CARE UNITS
|
Rapoport, J
|
|
2002
|
5 |
6 |
p. 458-
1 p.
|
artikel
|
| 22 |
IN1 A BAYESIAN APPROACH TO NET HEALTH BENEFITS:AN ILLUSTRATION AND APPLICATION TO MODELING HIV PREVENTION
|
Johnson-Masotti, A
|
|
2002
|
5 |
6 |
p. 445-446
2 p.
|
artikel
|
| 23 |
IN2 COST-EFFECTIVENESS (CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
|
Grima, DT
|
|
2002
|
5 |
6 |
p. 446-
1 p.
|
artikel
|
| 24 |
IN4 DISCOUNTING HEALTH BENEFITS:A NOVEL APPROACH TO ENSURE PROPER VALUING OF VACCINATION STRATEGIES
|
Bos, JM
|
|
2002
|
5 |
6 |
p. 453-
1 p.
|
artikel
|
| 25 |
IN5 ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL C VACCINATION PROGRAM IN THE NETHERLANDS
|
Welte, R
|
|
2002
|
5 |
6 |
p. 453-454
2 p.
|
artikel
|
| 26 |
IN3 METHODS FOR ASSESSING COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV:THE IMPACT OF USING AN EXTENDED STUDY PERIOD
|
Bos, JM
|
|
2002
|
5 |
6 |
p. 446-447
2 p.
|
artikel
|
| 27 |
IN6 PRIMARY CARE PRESCRIBING AND ANTIBIOTIC RESISTANCE:WHAT IS THE ADDED VALUE OF PERSON SPECIFIC DATA ABOUT ANTIBIOTIC PRESCRIBING COMPARED WITH EXISTING, PRACTICE LEVEL INFORMATION?
|
Davey, PG
|
|
2002
|
5 |
6 |
p. 454-
1 p.
|
artikel
|
| 28 |
MC2 A COST-EFFECTIVENESS ANALYSIS OF ORAL TRIPTAN THERAPIES
|
Yalkowsky, RB
|
|
2002
|
5 |
6 |
p. 455-
1 p.
|
artikel
|
| 29 |
MC1 DEVELOPMENT OF A FUNCTIONAL ASSESSMENT IN MIGRAINEURS MEASUREMENT TOOL BASED ON THE WHO'S ICIDH2 CLASSIFICATION
|
Pathak, D
|
|
2002
|
5 |
6 |
p. 454-455
2 p.
|
artikel
|
| 30 |
MC3 PROJECTIONS FOR COPD IN THE NETHERLANDS: HOW THE TYPE OF PROJECTION AFFECTS THE ESTIMATED GROWTH IN PREVALENCE
|
Feenstra, TL
|
|
2002
|
5 |
6 |
p. 455-
1 p.
|
artikel
|
| 31 |
MD4 CHANGES IN COST-EFFECTIVENESS OVER TIME:THE CASE OF EPOETIN ALFA FOR RENAL REPLACEMENT THERAPY PATIENTS IN THE UK
|
Remak, E
|
|
2002
|
5 |
6 |
p. 458-
1 p.
|
artikel
|
| 32 |
MD2 MEASURING HEALTH IMPACTS ON WORK PERFORMANCE: COMPARING SUBJECTIVE AND OBJECTIVE REPORTS
|
Pransky, G
|
|
2002
|
5 |
6 |
p. 448-449
2 p.
|
artikel
|
| 33 |
MD5 SHOULD THE EUROQOL DESCRIPTIVE SYSTEM BE EXTENDED FROM THREE TO FIVE LEVELS? A METHODOLOGICAL STRATEGY WITH AN EMPIRICAL PILOT
|
Janssen, MF
|
|
2002
|
5 |
6 |
p. 458-459
2 p.
|
artikel
|
| 34 |
MD1 THE EQUITY-EFFICIENCY TRADEOFF:WHAT IS THE SOCIAL INTERPRETATION OF EQUITY?
|
Pickee, S
|
|
2002
|
5 |
6 |
p. 448-
1 p.
|
artikel
|
| 35 |
MD3 VALIDATING A DISEASE MODEL ACCORDING TO CRITERIA OF EVIDENCE BASED MEDICINE
|
Schramm, W
|
|
2002
|
5 |
6 |
p. 449-
1 p.
|
artikel
|
| 36 |
MD6 WHAT IS “TIME” IN TIME PREFERENCE STUDIES?
|
Meerding, WJ
|
|
2002
|
5 |
6 |
p. 459-
1 p.
|
artikel
|
| 37 |
OD2 LONG-ACTING RISPERIDONE IN SCHIZOPHRENIC PATIENTS COMPARED WITH ORAL OLANZAPINE AND HALOPERIDOL DECANOATE:A COST-EFFECTIVENESS ANALYSIS
|
Llorca, PM
|
|
2002
|
5 |
6 |
p. 456-
1 p.
|
artikel
|
| 38 |
OD3 STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC VENOUS LEG ULCERS—THE CASE OF PROMOGRAN® IN A SWEDISH HEALTH CARE SETTING
|
Ghatnekar, O
|
|
2002
|
5 |
6 |
p. 456-457
2 p.
|
artikel
|
| 39 |
OD1 THE COST-EFFECTIVENESS OF RALOXIFENE COMPARED WITH NO DRUG THERAPY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES WHEN HRT IS INAPPROPRIATE: THE CASE OF AUSTRALIA
|
Davey, P
|
|
2002
|
5 |
6 |
p. 455-456
2 p.
|
artikel
|
| 40 |
PAR6 ANALYSIS OF CONSUMPTION OF NONSTEROID ANTIINFLAMMATORY DRUGS (GROUP M01) AT NATIONAL LEVEL IN DDD/1000/DAY: 1999–2001
|
Borissov, BN
|
|
2002
|
5 |
6 |
p. 477-
1 p.
|
artikel
|
| 41 |
PAR5 DISEASE SEVERITY AND COSTS AMONG PATIENTS STARTING A TREATMENT WITH COX-2 SPECIFIC INHIBITORS VERSUS NSAIDS PATIENTS IN ITALY: QUANTITATIVE ASSESSMENT IN 442 PATIENTS WITH ARTHRITIS
|
Lucioni, C
|
|
2002
|
5 |
6 |
p. 476-477
2 p.
|
artikel
|
| 42 |
PAR7 MODELLED COST-EFFECTIVENESS AND COSTUTILITY ANALYSIS OF VARIOUS TREATMENT STRATEGIES IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN IN POLAND
|
Orlewska, E
|
|
2002
|
5 |
6 |
p. 477-
1 p.
|
artikel
|
| 43 |
PAR1 PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDEMETHOTREXATE OR INFLIXIMABMETHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE
|
Rubio Terrés, C
|
|
2002
|
5 |
6 |
p. 475-
1 p.
|
artikel
|
| 44 |
PAR2 THE COST-EFFECTIVENESS ANALYSIS OF CELECOXIB AND NSAIDS WITH GASTROPROTECTIVE AGENTS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN UKRAINE
|
Zaliska, O
|
|
2002
|
5 |
6 |
p. 475-
1 p.
|
artikel
|
| 45 |
PAR3 VARIATION IN RESOURCE UTILIZATION AND TREATMENT COSTS FOR RHEUMATOID ARTHRITIS (RA) ACROSS 5 COUNTRIES IN AN ADALIMUMAB (D2E7) CLINICAL TRIAL
|
Van de Putte, L
|
|
2002
|
5 |
6 |
p. 475-476
2 p.
|
artikel
|
| 46 |
PCN16 A COMPARISON OF THE COSTS OF GEMCITABINE/CISPLATIN AND GEMCITABINE/CARBOPLATIN COMBINATION REGIMENS IN THE TREATMENT OF ADVANCED NSCLC IN THE UK AND FRANCE
|
Tilden, DP
|
|
2002
|
5 |
6 |
p. 542-
1 p.
|
artikel
|
| 47 |
PCN15 ANEMIA RESULTS IN INCREASED UTILIZATION IN CANCER PATIENTS
|
Gupta, S
|
|
2002
|
5 |
6 |
p. 542-
1 p.
|
artikel
|
| 48 |
PCN8 AVERAGE TOTAL COST OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS IN SPAIN USING VARIOUS CHEMOTHERAPY DOUBLETS
|
Kielhorn, A
|
|
2002
|
5 |
6 |
p. 539-
1 p.
|
artikel
|
| 49 |
PCN21 CANCER CHEMOTHERAPY AT HOME: FEASIBILITY, PATIENT OUTCOMES, AND HEALTHCARE SYSTEM IMPLICATIONS
|
Boothroyd, LJ
|
|
2002
|
5 |
6 |
p. 544-545
2 p.
|
artikel
|
| 50 |
PCN5 COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES
|
Glaspy, J
|
|
2002
|
5 |
6 |
p. 538-
1 p.
|
artikel
|
| 51 |
PCN17 COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES
|
Glaspy, J
|
|
2002
|
5 |
6 |
p. 543-
1 p.
|
artikel
|
| 52 |
PCN10 COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS
|
Postma, MJ
|
|
2002
|
5 |
6 |
p. 540-
1 p.
|
artikel
|
| 53 |
PCN1 COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA
|
Groot, MT
|
|
2002
|
5 |
6 |
p. 536-
1 p.
|
artikel
|
| 54 |
PCN2 COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION-ANALYSIS
|
Sroczynski, G
|
|
2002
|
5 |
6 |
p. 536-537
2 p.
|
artikel
|
| 55 |
PCN9 COST-EFFICACY OF ZOLEDRONIC 4MG ACID VS. PAMIDRONATE 90MG IN THE TREATMENT OF HYPERCALCEMIA OF MALIGNACY (HCM)
|
Badia, X
|
|
2002
|
5 |
6 |
p. 539-540
2 p.
|
artikel
|
| 56 |
PCN18 DERIVING A UTILITY WEIGHTED INDEX FROM CONDITION-SPECIFIC MEASURES: PRACTICAL SOLUTIONS FOR ECONOMIC EVALUTIONS
|
Kind, P
|
|
2002
|
5 |
6 |
p. 543-
1 p.
|
artikel
|
| 57 |
PCN6 ECONOMICAL EVALUATION OF RALTITREXED VERSUS FLUOROURACIL PLUS LEUCOVORIN (5-FU + LV) FOR TREATMENT OF ADVANCED COLORECTAL CANCER
|
Vorobyov, P
|
|
2002
|
5 |
6 |
p. 538-
1 p.
|
artikel
|
| 58 |
PCN19 EXAMINING PREFERENCES AND TIMETRADE-OFF UTILITY FOR GEMCITABINE PLUS CISPLATIN IN THE TREATMENT OF BLADDER CANCER:A SURVEY USING DISCRETE CHOICE CONJOINT ANALYSIS IN THE UK
|
Brown, A
|
|
2002
|
5 |
6 |
p. 543-544
2 p.
|
artikel
|
| 59 |
PCN13 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER:A MULTI-COUNTRY COSTMINIMISATION ANALYSIS
|
Aristides, M
|
|
2002
|
5 |
6 |
p. 541-
1 p.
|
artikel
|
| 60 |
PCN12 IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC): FOCUS ON TRASTUZUMAB (HERCEPTIN(H))
|
Miadi-Fargier, H
|
|
2002
|
5 |
6 |
p. 541-
1 p.
|
artikel
|
| 61 |
PCN4 IN THE UK GEMZAR DOUBLET HAS LOWEST TOTAL TREATMENT COSTS FOR NSCLC COMPARED TO FOUR OTHER CHEMOTHERAPY DOUBLETS
|
Aristides, M
|
|
2002
|
5 |
6 |
p. 541-542
2 p.
|
artikel
|
| 62 |
PCN20 IS THERE DIFFERENCE BETWEEN GEMCITABINE BASED NSCLC TREATMENT AND OTHER PLATINUM BASED COMBINATIONS FOR RESPONSE RATES AND TOXICITY?
|
Bhalla, S
|
|
2002
|
5 |
6 |
p. 544-
1 p.
|
artikel
|
| 63 |
PCN7 MAJOR DETERMINANTS OF COST IN ADVANCED NON-SMALL-CELL LUNG CANCER CHEMOTHERAPY REGIMES IN FRANCE
|
Tilden, D
|
|
2002
|
5 |
6 |
p. 538-539
2 p.
|
artikel
|
| 64 |
PCN4 ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM REDUCED RESOURCE UTILIZATION AND COSTS COMPARED WITH DAILY FILGRASTIM IN THE PREVENTION OF CHEMOTHERAPYINDUCED NEUTROPENIA
|
Green, MD
|
|
2002
|
5 |
6 |
p. 537-538
2 p.
|
artikel
|
| 65 |
PCN11 PROPENSITY ANALYSIS OF EPOETIN USE AND ITS IMPACT ON OVERALL COSTS OF CANCER CARE
|
Marchetti, M
|
|
2002
|
5 |
6 |
p. 540-541
2 p.
|
artikel
|
| 66 |
PCV31 ACCEPTANCE AND RELIABILITY OF A COSTMEASUREMENT QUESTIONNAIRE IN CARDIAC REHABILITATION
|
Schweikert, B
|
|
2002
|
5 |
6 |
p. 489-490
2 p.
|
artikel
|
| 67 |
PCV20 A COST EFFECTIVENESS ANALYSIS OF SPIRONOLACTONE IN THE MANAGEMENT OF PATIENTS WITH SEVERE CHRONIC HEART FAILURE (CHF) IN THE IRISH HEALTHCARE SETTING
|
Tilson, L
|
|
2002
|
5 |
6 |
p. 485-
1 p.
|
artikel
|
| 68 |
PCV56 ALLOCATION OF RESOURCES BETWEEN SMOKING CESSATION METHODS AND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA BASED ON COST-EFFECTIVENESS AND THE SOCIAL WELFARE FUNCTION
|
Plans-Rubió, P
|
|
2002
|
5 |
6 |
p. 499-
1 p.
|
artikel
|
| 69 |
PCV1 AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS: HIGH RISK POPULATIONS
|
Levy, E
|
|
2002
|
5 |
6 |
p. 477-478
2 p.
|
artikel
|
| 70 |
PCV22 A PHARMACOECONOMIC EVALUATION OF AGGRESSIVE LIPID-LOWERING THERAPY COMPARED WITH ANGIOPLASTY IN STABLE CORONARY ARTERY DISEASE IN SPAIN
|
Domingo, E
|
|
2002
|
5 |
6 |
p. 486-
1 p.
|
artikel
|
| 71 |
PCV39 A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION
|
Richard, LJ
|
|
2002
|
5 |
6 |
p. 492-493
2 p.
|
artikel
|
| 72 |
PCV40 COMORBIDITIES CAUSING INCREASING MORTALITY AT AGES UNDER 65 IN CARDIOVASCULAR DISEASE AND HYPERTENSION
|
Farquhar, IV
|
|
2002
|
5 |
6 |
p. 493-
1 p.
|
artikel
|
| 73 |
PCV27 COMPARING RESOURCE USE INTENSITY IN THREE POPULATIONS WITH ATHEROTHROMBOSIS
|
Migliaccio-Walle, K
|
|
2002
|
5 |
6 |
p. 488-
1 p.
|
artikel
|
| 74 |
PCV46 CORRELATES OF SATISFACTION WITH PAIN CONTROL AMONG CARDIOVASCULAR PATIENTS IN THE US (2001)
|
Wolosin, RJ
|
|
2002
|
5 |
6 |
p. 495-
1 p.
|
artikel
|
| 75 |
PCV12 COST-EFFECTIVENES OF ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN BRAZIL
|
Nuijten, MJC
|
|
2002
|
5 |
6 |
p. 482-
1 p.
|
artikel
|
| 76 |
PCV4 COST-EFFECTIVENESS ANALYSIS OF N-3 POLYUNSATURED FATTY ACIDS (PUFA) AFTER MYOCARDIAL INFARCTION, FRENCH ASSESSMENT
|
Taïeb, C
|
|
2002
|
5 |
6 |
p. 479-
1 p.
|
artikel
|
| 77 |
PCV17 COST-EFFECTIVENESS ANALYSIS OF TREATMENTS TO REDUCE CHOLESTEROL CONCENTRATION, BLOOD PRESSURE AND SMOKING FOR THE PREVENTION OF CORONARY HEART DISEASE
|
Plans-Rubió, P
|
|
2002
|
5 |
6 |
p. 484-
1 p.
|
artikel
|
| 78 |
PCV33 COST-EFFECTIVENESS OF METHODS TO QUIT SMOKING IN FINNISH HEALTH CARE
|
Jormanainen, VJ
|
|
2002
|
5 |
6 |
p. 490-
1 p.
|
artikel
|
| 79 |
PCV34 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY
|
Postma, MJ
|
|
2002
|
5 |
6 |
p. 490-491
2 p.
|
artikel
|
| 80 |
PCV24 COST-EFFECTIVENSS OF ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE
|
You, JH
|
|
2002
|
5 |
6 |
p. 487-
1 p.
|
artikel
|
| 81 |
PCV5 COST IMPACT OF AMLODIPINE IN BRITISH COLUMBIA BASED ON THE PREVENT TRIAL RESULTS
|
Ali, F
|
|
2002
|
5 |
6 |
p. 479-
1 p.
|
artikel
|
| 82 |
PCV13 COST OF MANAGING UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD:A EUROPEAN APPROACH
|
Gabriel, S
|
|
2002
|
5 |
6 |
p. 482-
1 p.
|
artikel
|
| 83 |
PCV10 COST OF UNCONTROLLED HYPERTENSION IN CANADA
|
Ali, F
|
|
2002
|
5 |
6 |
p. 481-
1 p.
|
artikel
|
| 84 |
PCV35 COSTS OF STROKE:A COMPARISON OF REGULAR CARE AND THREE EXPERIMENTAL STROKE SERVICES IN THE NETHERLANDS
|
Van Exel, J
|
|
2002
|
5 |
6 |
p. 491-
1 p.
|
artikel
|
| 85 |
PCV45 DETERMINANTS OF FIRST-YEAR QUALITY OF LIFE (QOL) AFTER SURGERY—INTERIM ANALYSIS OF A RANDOMISED TRIAL WITH LAPBAND-SURGERY AND VERTICAL BANDED GASTROPLASTY (VBG)
|
Mastrigt van, G
|
|
2002
|
5 |
6 |
p. 495-
1 p.
|
artikel
|
| 86 |
PCV37 DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?
|
Gwadry-Sridhar, F
|
|
2002
|
5 |
6 |
p. 492-
1 p.
|
artikel
|
| 87 |
PCV14 ECONOMIC EVALUATION OF A COMPLIANCE PROGRAM IN PATIENTS WITH STATIN THERAPY—DESIGN AND PILOT PHASE OF THE ORBITAL STUDY
|
Upmeier, H
|
|
2002
|
5 |
6 |
p. 483-
1 p.
|
artikel
|
| 88 |
PCV25 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH ATORVASTATIN:AN ITALIAN PERSPECTIVE
|
Mantovani, LG
|
|
2002
|
5 |
6 |
p. 487-
1 p.
|
artikel
|
| 89 |
PCV7 ECONOMIC EVALUATION OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT):AN ITALIAN CUSTOMIZATION
|
Ruffo, P
|
|
2002
|
5 |
6 |
p. 480-
1 p.
|
artikel
|
| 90 |
PCV8 ECONOMIC EVALUATION OF THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES):AN ITALIAN CUSTOMIZATION
|
Bustacchini, S
|
|
2002
|
5 |
6 |
p. 480-
1 p.
|
artikel
|
| 91 |
PCV21 ECONOMIC EVALUATION OF THE PROSPECTIVE RANDOMIZED EVALUATION OF VASCULAR EFFECT OF NORVASC STUDY (PREVENT):AN ITALIAN CUSTOMIZATION
|
Mantovani, LG
|
|
2002
|
5 |
6 |
p. 485-486
2 p.
|
artikel
|
| 92 |
PCV50 EVALUATION OF NITRATE PRESCRIPTION PATTERNS AMONG PHYSICIANS FROM DIFFERENT SPECIALITIES IN ISRAEL
|
Reuveni, H
|
|
2002
|
5 |
6 |
p. 497-
1 p.
|
artikel
|
| 93 |
PCV57 IMPLICATIONS OF TREATMENT GUIDELINES: WHAT STATINS DO WE REALLY NEED?
|
Haiderali, A
|
|
2002
|
5 |
6 |
p. 499-500
2 p.
|
artikel
|
| 94 |
PCV16 INCIDENCE AND ECONOMIC BURDEN OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN HONG KONG
|
Lee, KK
|
|
2002
|
5 |
6 |
p. 483-484
2 p.
|
artikel
|
| 95 |
PCV53 INFLUENCE OF THREE HYPERTENSION GUIDELINES ON RATES OF TREATMENT INDICATION
|
Rosery, H
|
|
2002
|
5 |
6 |
p. 498-
1 p.
|
artikel
|
| 96 |
PCV43 IS THERE ANY RELATIONSHIP BETWEEN COMPLIANCE AND HRQOL IN PATIENTS WITH HEART FAILURE?
|
Gwadry-Sridhar, F
|
|
2002
|
5 |
6 |
p. 494-
1 p.
|
artikel
|
| 97 |
PCV38 LIPID LOWERING MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES
|
Brophy, J
|
|
2002
|
5 |
6 |
p. 492-
1 p.
|
artikel
|
| 98 |
PCV52 LOW LEVEL OF CONSISTENCY BETWEEN QUALITATIVE (NCEP-II) AND QUANTITATIVE METHODS TO RECOMMEND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA IN INDIVIDUALS WITHOUT CORONARY HEART DISEASE
|
Plans-Rubió, P
|
|
2002
|
5 |
6 |
p. 498-
1 p.
|
artikel
|
| 99 |
PCV15 MANAGEMENT EFFECTIVENESS AND COST/UTILITY RATIO IN CHRONIC HEART FAILURE: COMPARISON BETWEEN HEART FAILURE MANAGEMENT PROGRAM DELIVERED BY DAY-HOSPITAL AND USUAL CARE
|
Capomolla, S
|
|
2002
|
5 |
6 |
p. 483-
1 p.
|
artikel
|
| 100 |
PCV36 OBESITY AND POTENTIAL COST OFFSETS FROM WEIGHT LOSS—FINDINGS FROM THE SWEDISH MALMO PREVENTION STUDY
|
Persson, U
|
|
2002
|
5 |
6 |
p. 491-492
2 p.
|
artikel
|
| 101 |
PCV9 OUTCOMES AND COSTS OF THROMBOPROPHYLAXIS WITH LOWMOLECULAR WEIGHT HEPARIN IN ACUTELYILL MEDICAL INPATIENTS
|
Thompson, D
|
|
2002
|
5 |
6 |
p. 481-
1 p.
|
artikel
|
| 102 |
PCV28 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT:AN EVALUATION BASED ON A BAYESIAN COST-EFFECTIVENESS APPROACH
|
Baio, G
|
|
2002
|
5 |
6 |
p. 488-
1 p.
|
artikel
|
| 103 |
PCV23 PHARMACOECONOMIC COMPARISON OF THE ANTIHYPERTENSIVE TREATMENT WITH TWO DIFFERENT ANGIOTENSINE CONVERTING ENZYME INHIBITORS: PERINDOPRIL AND ENALAPRIL
|
Hermanowski, T
|
|
2002
|
5 |
6 |
p. 486-487
2 p.
|
artikel
|
| 104 |
PCV2 PHYSICIAN CHARACTERISTICS OF THE NAVIGATOR TRIAL PREDICT AVERAGE LENGTH OF STAY (ALOS) IN ACUTE CORONARY SYNDROME (ACS)
|
Friedman, JY
|
|
2002
|
5 |
6 |
p. 478-
1 p.
|
artikel
|
| 105 |
PCV51 POSSIBILITIES OF NEW TECHNOLOGIES AMONG PATIENTS WITH HYPERTENSION: FEASIBILITY AND ACCEPTANCE OF AN EDUCATIVE INTERVENTION THROUGH SHORT MESSAGES TO THE PATIENT'S CELLULAR PHONE
|
De la Figuera, M
|
|
2002
|
5 |
6 |
p. 497-
1 p.
|
artikel
|
| 106 |
PCV30 PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-EFFECTIVENESS IN SECONDARY PREVENTION OF ISCHEMIC EVENTS
|
Lennes, X
|
|
2002
|
5 |
6 |
p. 489-
1 p.
|
artikel
|
| 107 |
PCV58 RANDOMIZED CONTROLLED INTERVENTION IN CARDIOVASCULAR DRUG TREATMENT IN NURSING HOMES
|
Ulfvarson, J
|
|
2002
|
5 |
6 |
p. 500-
1 p.
|
artikel
|
| 108 |
PCV11 RESOURCE UTILIZATION DURING THE FOUR MONTHS FOLLOWING A DIAGNOSIS OF DEEP VENOUS THROMBOSIS
|
Kahn, SR
|
|
2002
|
5 |
6 |
p. 481-482
2 p.
|
artikel
|
| 109 |
PCV41 SCREENING FOR ANEURYSMS AFTER SUCCESSFUL TREATMENT FOR SUBARACHNOID HAEMORRHAGE: DO WE HAVE THE EVIDENCE?
|
Buskens, E
|
|
2002
|
5 |
6 |
p. 493-494
2 p.
|
artikel
|
| 110 |
PCV54 SMOKING CESSATION: RELEVANCE IN THE UNDER 25 GROUP
|
Taïeb, C
|
|
2002
|
5 |
6 |
p. 498-499
2 p.
|
artikel
|
| 111 |
PCV55 SMOKING DEPENDENCY:AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP
|
Taïeb, C
|
|
2002
|
5 |
6 |
p. 499-
1 p.
|
artikel
|
| 112 |
PCV18 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442— TWO-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY
|
Rychlik, R
|
|
2002
|
5 |
6 |
p. 484-485
2 p.
|
artikel
|
| 113 |
PCV47 THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE
|
Gwadry-Sridhar, F
|
|
2002
|
5 |
6 |
p. 496-
1 p.
|
artikel
|
| 114 |
PCV6 THE COST COMPARISON OF CARDIOVERSION AND ANTIARRHYTHMIC THERAPY IN NONVALVULAR CHRONIC ATRIAL FIBRILLATION
|
Pietrasik, AL
|
|
2002
|
5 |
6 |
p. 479-480
2 p.
|
artikel
|
| 115 |
PCV29 THE COST-EFFECTIVENESS OF DIAGNOSTIC STRATEGIES WITH ANGIOGRAPHY AND/OR DUPLEX SCANNING FOR AORTOILIAC AND FEMOROPOPLITEAL ARTERIAL DISEASE
|
Coffi, S
|
|
2002
|
5 |
6 |
p. 489-
1 p.
|
artikel
|
| 116 |
PCV26 THE HEALTH ECONOMIC IMPLICATIONS OF TREATING ANEMIA IN PATIENTS WITH CONGESTIVE HEART FAILURE
|
Caro, J
|
|
2002
|
5 |
6 |
p. 487-488
2 p.
|
artikel
|
| 117 |
PCV44 THE IMPACT OF AN EDUCATIONAL INTERVENTION ON MULTIPLE HEALTH REALTED QUALITY OF LIFE MEASURES IN PATIENTS WITH HEART FAILURE (HF)
|
Gwadry-Sridhar, F
|
|
2002
|
5 |
6 |
p. 494-495
2 p.
|
artikel
|
| 118 |
PCV49 THE INFLUENCE OF COPAYMENTS ON THE DEMAND FOR DRUGS WITH THERAPEUTIC COMPETITORS:THE STATINS
|
Esposito, D
|
|
2002
|
5 |
6 |
p. 496-497
2 p.
|
artikel
|
| 119 |
PCV32 THE USE OF STATINS IN SECONDARY CARE: EVIDENCE FROM ACTUAL PRACTICE DATA
|
Degli Esposti, L
|
|
2002
|
5 |
6 |
p. 490-
1 p.
|
artikel
|
| 120 |
PCV19 TWO METHODS OF ASSESSING COSTS OF PHARMACOLOGICAL TREATMENT ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND
|
Czech, M
|
|
2002
|
5 |
6 |
p. 485-
1 p.
|
artikel
|
| 121 |
PCV42 UNCERTAINTIES IN COST-EFFECTIVENESS EVALUATION OF CAROTID ANGIOPLASTY AND STENTING
|
Janssen, MP
|
|
2002
|
5 |
6 |
p. 494-
1 p.
|
artikel
|
| 122 |
PCV48 WHAT IS THE WILLINGNESS TO PAY FOR FUTURE HEALTH BENEFITS AMONG HYPERTENSIVE PATIENTS—A PILOT STUDY IN POLISH SETTING
|
Czech, M
|
|
2002
|
5 |
6 |
p. 496-
1 p.
|
artikel
|
| 123 |
PDB10 A CROSS-OVER RANDOMISED CONTROLLED TRIAL TO COMPARE PSYCHOLOGICAL BARRIERS TO INSULIN SELF-INJECTION WITH THE INNOLET AND VIAL/SYRINGE
|
Skovlund, SE
|
|
2002
|
5 |
6 |
p. 549-
1 p.
|
artikel
|
| 124 |
PDB2 COST-EFFECTIVENESS ANALYSIS OF GLYCEMIC CONTROL WITH PIOGLITAZONE HYDROCHLORIDE FOR JAPANESE PATIENTS WITH TYPE II DIABETES
|
Ikeda, S
|
|
2002
|
5 |
6 |
p. 545-
1 p.
|
artikel
|
| 125 |
PDB1 COST-EFFECTIVENESS OF SWITCHING PATIENTS TO COMBINED GLIBENCLAMIDE AND METFORMIN (GLUCOVANCE) WHEN POORLY CONTROLLED WITH METFORMIN MONOTHERAPY:THE FRENCH PERSPECTIVE
|
Roze, S
|
|
2002
|
5 |
6 |
p. 545-
1 p.
|
artikel
|
| 126 |
PDB9 DEVELOPMENT AND VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)
|
Anderson, RT
|
|
2002
|
5 |
6 |
p. 548-
1 p.
|
artikel
|
| 127 |
PDB3 INTENSIVE LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS: MODELING THE LONG-TERM HEALTH ECONOMICS IMPLICATIONS OF THE DIABETES PREVENTION PROGRAM IN THE FRENCH, GERMAN, AND UK SETTINGS
|
Palmer, AJ
|
|
2002
|
5 |
6 |
p. 545-546
2 p.
|
artikel
|
| 128 |
PDB5 LONG-TERM CONSEQUENCES FOR THE TREATMENT OF HYPERTENSIVE DIABETES TYPE 2 PATIENTS WITH A FIXED COMBINATION OF AN ACE-INHIBITOR AND NON-DIHYDROPYRIDINE-CALCIUM-CHANNELBLOCKER IN COMPARISON TO OTHER COMBINATION THERAPIES
|
Maxion-Bergemann, S
|
|
2002
|
5 |
6 |
p. 546-547
2 p.
|
artikel
|
| 129 |
PDB14 MEDICAID MANAGED CARE QUALITY AMONG BLACK AND WHITE ADULTS WITH DIABETES MELLITUS
|
Mayberry, RM
|
|
2002
|
5 |
6 |
p. 550-
1 p.
|
artikel
|
| 130 |
PDB13 REAL WORLD ADHERENCE BENEFITS FROM COMBINATION PRODUCTS UTILIZED IN DIABETICS: SULFONYLUREAS & METFORMIN
|
Schaffer, M
|
|
2002
|
5 |
6 |
p. 550-
1 p.
|
artikel
|
| 131 |
PDB6 RETROSPECTIVE STUDY EVALUATING CLINICAL AND ECONOMIC OUTCOMES OF MONOTHERAPY VERSUS DUAL THERAPY IN DIABETIC PATIENTS IN A COUNTY HEALTH CARE SYSTEM
|
Lal, LS
|
|
2002
|
5 |
6 |
p. 547-
1 p.
|
artikel
|
| 132 |
PDB9 SELF-ASSESSMENT OF DIABETES CONTROL: ACCURACY OF PATIENTS' PERCEPTIONS
|
Bolge, SC
|
|
2002
|
5 |
6 |
p. 549-550
2 p.
|
artikel
|
| 133 |
PDB4 THE HEALTH-ECONOMIC IMPLICATIONS OF THE “IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL” (IDNT) IN FRANCE AND BELGIUM
|
Palmer, AJ
|
|
2002
|
5 |
6 |
p. 546-
1 p.
|
artikel
|
| 134 |
PDB7 THE WHO/IDF CARECARD DIABETES AS AN INTERNET-BASED APPROACH FOR QUALITY ASSURANCE IN SWITZERLAND
|
Schramm, W
|
|
2002
|
5 |
6 |
p. 547-548
2 p.
|
artikel
|
| 135 |
PDB8 TYPE-2 DIABETES AND BODY MASS INDEX (BMI):WHAT CAN WE LEARN FROM A LONGITUDINAL DATABASE STUDY?
|
Charpentier, G
|
|
2002
|
5 |
6 |
p. 548-
1 p.
|
artikel
|
| 136 |
PDB11 TYPE 1 DIABETES, LONG-TERM COMPLICATIONS AND QUALITY OF LIFE MEASURED WITH RAND-36 HEALTH PROFILE MEASURE
|
Hahl, J
|
|
2002
|
5 |
6 |
p. 549-
1 p.
|
artikel
|
| 137 |
PDB15 USE OF THE PATIENT ANALYSIS & TRACKING SYSTEM (PATS) IN ASSESSMENT OF RATIONAL PHARMACOTHERAPY OF DIABETICS IN A BIG HOSPITAL
|
Sechser, T
|
|
2002
|
5 |
6 |
p. 551-
1 p.
|
artikel
|
| 138 |
PES4 A DISEASE SEVERITY STAGING SYSTEM FOR MEASURING THE COST OF GLAUCOMA PROGRESSION IN EUROPE
|
Doyle, J
|
|
2002
|
5 |
6 |
p. 552-
1 p.
|
artikel
|
| 139 |
PES25 ASSESSMENT OF THE DERMATOLOGIC LIFE QUALITY INDEX (DLQI) IN CHRONIC IDIOPATHIC URTICARIA
|
Lennox, R
|
|
2002
|
5 |
6 |
p. 560-
1 p.
|
artikel
|
| 140 |
PES12 BURDEN OF ATOPIC DERMATITIS IN SWITZERLAND
|
Kugland, B
|
|
2002
|
5 |
6 |
p. 555-
1 p.
|
artikel
|
| 141 |
PES9 COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES
|
Lilliu, H
|
|
2002
|
5 |
6 |
p. 554-
1 p.
|
artikel
|
| 142 |
PES1 COST EFFECTIVENESS OF PIMECROLIMUS (ELIDEL) IN THE TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS
|
Grueger, J
|
|
2002
|
5 |
6 |
p. 556-
1 p.
|
artikel
|
| 143 |
PES1 COST OF ILLNESS OF GLAUCOMA IN CANADA: ANALYSES BASED ON VISUAL FIELD MEASUREMENTS AND PHYSICIAN'S ASSESSMENT
|
Iskedjian, M
|
|
2002
|
5 |
6 |
p. 551-
1 p.
|
artikel
|
| 144 |
PES5 COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
|
Lilliu, H
|
|
2002
|
5 |
6 |
p. 552-553
2 p.
|
artikel
|
| 145 |
PES7 COST-UTILITY OF VITAMINS FOR THE TREATMENT OF MACULAR DEGENERATION
|
Sharma, S
|
|
2002
|
5 |
6 |
p. 553-554
2 p.
|
artikel
|
| 146 |
PES20 DERIVATION OF SYMPTOMS SCORES AND QOL SCORES FROM CLINICAL DATA IN SEASONAL ALLERGIC CONJUNCTIVITIS
|
Le Pen, C
|
|
2002
|
5 |
6 |
p. 558-559
2 p.
|
artikel
|
| 147 |
PES11 ECONOMIC EVALUATION OF METHOTREXATE AND CYCLOSPORIN A FOR PATIENTS WITH SEVERE PSORIASIS
|
Opmeer, B
|
|
2002
|
5 |
6 |
p. 555-
1 p.
|
artikel
|
| 148 |
PES26 HEALTH STATE UTILITIES IN PATIENTS WITH DERMATOLOGICAL PROBLEMS—A POPULATION STUDY
|
Bingefors, C
|
|
2002
|
5 |
6 |
p. 560-561
2 p.
|
artikel
|
| 149 |
PES22 IMPACT OF CHILDREN'S SKIN DISEASES ON THEIR PARENTS' QUALITY OF LIFE
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 559-
1 p.
|
artikel
|
| 150 |
PES21 IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS' SUFFERING FROM SKIN DISEASES
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 559-
1 p.
|
artikel
|
| 151 |
PES19 INITIAL DEVELOPMENT AND VALIDATION OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)
|
Buchholz, P
|
|
2002
|
5 |
6 |
p. 558-
1 p.
|
artikel
|
| 152 |
PES3 LIFE-LONG SOCIETAL NET VALUE OF GLAUCOMA TREATMENT:A MARKOV MODEL APPROACH
|
Lafuma, A
|
|
2002
|
5 |
6 |
p. 552-
1 p.
|
artikel
|
| 153 |
PES8 LOW VISUAL ACUITY AND BLINDNESS SOCIAL COSTS IN FRANCE
|
Lafuma, A
|
|
2002
|
5 |
6 |
p. 554-
1 p.
|
artikel
|
| 154 |
PES16 MEDICAL OUTCOME OF GLAUCOMA TREATMENT IN FRANCE
|
Denis, P
|
|
2002
|
5 |
6 |
p. 557-
1 p.
|
artikel
|
| 155 |
PES2 MEDICAL PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COSTS IN FRANCE
|
Denis, P
|
|
2002
|
5 |
6 |
p. 551-552
2 p.
|
artikel
|
| 156 |
PES6 PATIENT REPORTED OUTCOMES AND HEATH SYSTEM ECONOMIC IMPACT OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2% PATIENT OUTCOMES
|
Buchholz, PM
|
|
2002
|
5 |
6 |
p. 553-
1 p.
|
artikel
|
| 157 |
PES10 PHARMACOECONOMIC EVALUATION OF A NEW TWO COMPOUND OINTMENT (DAIVOBET®) AND CALCIPOTRIOL (DAIVONEX®) IN THE TREATMENT OF PSORIASIS VULGARIS IN SWEDEN
|
Sørensen, M
|
|
2002
|
5 |
6 |
p. 554-555
2 p.
|
artikel
|
| 158 |
PES17 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 557-
1 p.
|
artikel
|
| 159 |
PES23 PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS
|
Finlay, A
|
|
2002
|
5 |
6 |
p. 559-560
2 p.
|
artikel
|
| 160 |
PES24 PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY: FRENCH RESULTS
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 560-
1 p.
|
artikel
|
| 161 |
PES13 RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY
|
Ehlken, B
|
|
2002
|
5 |
6 |
p. 555-556
2 p.
|
artikel
|
| 162 |
PES15 USING A DISCRIMINANT FUNCTION TO MODEL THE LONG-TERM VISUAL FIELD CONSEQUENCES OF IOP CONTROL:A CASE STUDY BASED ON A TIMOLOL, LATANOPROST AND TRAVOPROST CLINICAL TRIAL
|
Nordmann, JP
|
|
2002
|
5 |
6 |
p. 556-557
2 p.
|
artikel
|
| 163 |
PES18 VISION RELATED QUALITY OF LIFE OF FRENCH PATIENTS IS AFFECTED BY TOPICAL GLAUCOMA TREATMENT SIDE EFFECTS
|
Nordmann, J
|
|
2002
|
5 |
6 |
p. 557-558
2 p.
|
artikel
|
| 164 |
PGS5 A COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE VS. OMEPRAZOLE IN THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS IN GREECE
|
Karokis, A
|
|
2002
|
5 |
6 |
p. 502-
1 p.
|
artikel
|
| 165 |
PGS7 ANALYSIS OF RESOURCE USE AND COSTS ASSOCIATED WITH MINOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) RELATED GASTRO-INTESTINAL (GI) EVENTS
|
Annemans, L
|
|
2002
|
5 |
6 |
p. 503-
1 p.
|
artikel
|
| 166 |
PGS14 CORRELATION BETWEEN DIFFERENT PRODUCTIVITY VARIABLES OBTAINED FROM THE WPAI-GERD QUESTIONNAIRE
|
Wahlqvist, P
|
|
2002
|
5 |
6 |
p. 505-506
2 p.
|
artikel
|
| 167 |
PGS6 COST COMPARISON OF ESOMEPRAZOLE BASED AND OMEPRAZOLE BASED HELICOBACTER PYLORI ERADICATION STRATEGIES IN DUODENAL ULCER DISEASE IN GREECE
|
Christodoulopoulou, A
|
|
2002
|
5 |
6 |
p. 502-503
2 p.
|
artikel
|
| 168 |
PGS2 ECONOMIC BURDEN OF IBS
|
Badia, X
|
|
2002
|
5 |
6 |
p. 501-
1 p.
|
artikel
|
| 169 |
PGS1 EMPLOYMENT LOSSES RELATED TO INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: RESULTS FROM THE NATIONAL INTERVIEW SURVEY
|
Longobardi, T
|
|
2002
|
5 |
6 |
p. 500-
1 p.
|
artikel
|
| 170 |
PGS16 EVALUATION OF THE USE OF PROTON PUMP INHIBITORS IN A PUBLIC HOSPITAL IN HONG KONG
|
Lee, VW
|
|
2002
|
5 |
6 |
p. 506-
1 p.
|
artikel
|
| 171 |
PGS15 FORMULARY CONVERSION OF PROTON PUMP INHIBITORS: MONITORING FOR POTENTIAL DRUG INTERACTION
|
DeLattre, ML
|
|
2002
|
5 |
6 |
p. 506-
1 p.
|
artikel
|
| 172 |
PGS3 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF TREATING NSAID-ASSOCIATED GASTROINTESTINAL TOXICITY IN JAPAN: FEASIBILITY OF A DELPHI-PANEL APPROACH IN JAPAN
|
Kamae, I
|
|
2002
|
5 |
6 |
p. 501-
1 p.
|
artikel
|
| 173 |
PGS13 HEALTH STATE UTILITIES AND WILLINGNESS TO PAY IN GERD PATIENTS WITH HEARTBURN
|
Kartman, B
|
|
2002
|
5 |
6 |
p. 505-
1 p.
|
artikel
|
| 174 |
PGS11 IMPACT OF IBS ON QUALITY OF LIFE AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AND RELATIVES
|
Badia, X
|
|
2002
|
5 |
6 |
p. 504-
1 p.
|
artikel
|
| 175 |
PGS12 IRRITABLE BOWEL SYNDROME (IBS) SIGNIFICANTLY AFFECTS PATIENT QUALITY OF LIFE (QOL) AND IS RESPONSIBLE FOR HIGH COSTS IN FRANCE:THE ENCOLI STUDY
|
Brun-Strang, C
|
|
2002
|
5 |
6 |
p. 505-
1 p.
|
artikel
|
| 176 |
PGS4 LOW-DOSE PPI AND STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD—A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL
|
You, JH
|
|
2002
|
5 |
6 |
p. 501-502
2 p.
|
artikel
|
| 177 |
PGS8 META-ANALYSIS OF ESOMEPRAZOLE 40MG AND LANSOPRAZOLE 30MG IN THE HEALING OF REFLUX OESOPHAGITIS
|
Edwards, S
|
|
2002
|
5 |
6 |
p. 503-
1 p.
|
artikel
|
| 178 |
PGS9 OUTCOMES ANALYSIS OF RABEPRAZOLE (ACIPHEX) USE AT A VETERAN AFFAIRS MEDICAL CENTER
|
Gordon, M
|
|
2002
|
5 |
6 |
p. 503-504
2 p.
|
artikel
|
| 179 |
PGS10 TOWARDS A MULTISTAGE DECISION ANALYSIS FOR THE TREATMENT OF FAECAL INCONTINENCE
|
Dijkgraaf, M
|
|
2002
|
5 |
6 |
p. 504-
1 p.
|
artikel
|
| 180 |
PHP8 AN ECONOMIC MODEL FOR COOPERATION BETWEEN A NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT PROGRAM:TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION
|
Shavit, O
|
|
2002
|
5 |
6 |
p. 467-
1 p.
|
artikel
|
| 181 |
PHP1 ASSESSMENT OF PROPOSED GUIDELINES FOR PHARMACOECONOMIC SUBMISSIONS IN GREECE: OVERVIEW AND IMPLEMENTATION PROBLEMS
|
Geitona, M
|
|
2002
|
5 |
6 |
p. 464-
1 p.
|
artikel
|
| 182 |
PHP5 “AUT IDEM”—250 MILLION € SAVINGS P. A. FOR STATUARY HEALTH INSURANCE IN GERMANY?
|
Pirk, O
|
|
2002
|
5 |
6 |
p. 465-466
2 p.
|
artikel
|
| 183 |
PHP26 CLASSIFICATION AND REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCEAND CONSENSUS-BASED GUIDELINES
|
Marchetti, M
|
|
2002
|
5 |
6 |
p. 474-
1 p.
|
artikel
|
| 184 |
PHP11 DESCRIPTIVE AND COMPARATIVE STUDY OF PATIENT-MANAGEMENT BY HOMEOPATHIC GPS VERSUS ALLOPATHIC GPS
|
Vainchtock, A
|
|
2002
|
5 |
6 |
p. 468-
1 p.
|
artikel
|
| 185 |
PHP6 DRUG COSTS REGULATION SYSTEM IN THE SLOVAK REPUBLIC
|
Tomek, D
|
|
2002
|
5 |
6 |
p. 466-
1 p.
|
artikel
|
| 186 |
PHP28 ECONOMIC STUDY OF MALNUTRITION IN ELDERLY PATIENTS LIVING IN THE COMMUNITY: USE OF PROPENSITY SCORE TO ANALYZE OBSERVATIONAL DATA
|
Schmitt, C
|
|
2002
|
5 |
6 |
p. 474-475
2 p.
|
artikel
|
| 187 |
PHP18 ESTIMATING THE ECONOMIC BURDEN OF HOSPITALIZATION DUE TO PATIENT NONADHERENCE IN CANADA
|
Iskedjian, M
|
|
2002
|
5 |
6 |
p. 470-471
2 p.
|
artikel
|
| 188 |
PHP16 GENERIC DRUG PRICES ARE TYPICALLY HIGHER IN CANADA THAN IN THE UNITED STATES
|
Palmer, WN
|
|
2002
|
5 |
6 |
p. 470-
1 p.
|
artikel
|
| 189 |
PHP20 HARMONIZATION OF HOSPITAL COSTS
|
Jacobs, P
|
|
2002
|
5 |
6 |
p. 471-472
2 p.
|
artikel
|
| 190 |
PHP19 HEALTH EXPENDITURE FOR THE DURATION OF LAST YEAR OF LIFE IN TAIWAN
|
Liang, LY
|
|
2002
|
5 |
6 |
p. 471-
1 p.
|
artikel
|
| 191 |
PHP27 HEALTH STATE VALUATIONS IN SUMMARY MEASURES OF POPULATION HEALTH
|
Salomon, J
|
|
2002
|
5 |
6 |
p. 474-
1 p.
|
artikel
|
| 192 |
PHP3 IMPROVING PATIENT ACCESS TO INNOVATION—THE NEW BELGIAN REIMBURSEMENT PROCEDURE
|
Umbach, I
|
|
2002
|
5 |
6 |
p. 465-
1 p.
|
artikel
|
| 193 |
PHP12 INFLUENCING PRESCRIBING IN ENGLISH PRIMARY CARE: FINDINGS FROM THE MANMED SURVEY
|
Mason, A
|
|
2002
|
5 |
6 |
p. 469-
1 p.
|
artikel
|
| 194 |
PHP14 MANAGING THERAPEUTICS NOVELTIES USING A SCIENTIFIC EVIDENCE-BASED METHOD
|
Catalan, A
|
|
2002
|
5 |
6 |
p. 469-
1 p.
|
artikel
|
| 195 |
PHP25 METHODOLOGICAL ISSUES: RESOURCE-BASED ZERO WORK HOUR PROCEDURES IN U.S. PHYSICIANS' OFFICES
|
Baker, JJ
|
|
2002
|
5 |
6 |
p. 473-
1 p.
|
artikel
|
| 196 |
PHP7 MODELLING, ECONOMIC EVALUATIONS, AND THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES:A SURVEY OF 38 GUIDELINES IN THE NETHERLANDS
|
Redekop, WK
|
|
2002
|
5 |
6 |
p. 466-
1 p.
|
artikel
|
| 197 |
PHP4 OUT-OF-POCKET PAYMENT IN BELGIUM:AN ANALYSIS IN RELATION TO PATHOLOGY
|
Ooms, D
|
|
2002
|
5 |
6 |
p. 465-
1 p.
|
artikel
|
| 198 |
PHP9 RISK SHARING IN A STATE FUNDED HEALTH SERVICE: OUTCOMES GUARANTEE PROJECT
|
Chapman, SR
|
|
2002
|
5 |
6 |
p. 467-
1 p.
|
artikel
|
| 199 |
PHP12 SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFERS AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLES THE DERIVATION OF PRACTICEWIDE TREATMENT GUIDELINES
|
Schmeichel, CJ
|
|
2002
|
5 |
6 |
p. 468-
1 p.
|
artikel
|
| 200 |
PHP17 SPANISH NATIONAL HEALTH SERVICE (NHS): PHARMACEUTICAL CONSUMPTION AND ESTIMATION OF THE SAVING WITH GENERIC DRUG PRESCRIPTIONS
|
Gaspar, D
|
|
2002
|
5 |
6 |
p. 470-
1 p.
|
artikel
|
| 201 |
PHP23 THE CONTRIBUTION OF HEALTH ECONOMICS TO PORTFOLIO MANAGEMENT DECISIONS:A VACCINE INDUSTRY EXAMPLE
|
Staginnus, U
|
|
2002
|
5 |
6 |
p. 472-473
2 p.
|
artikel
|
| 202 |
PHP15 THE USE OF PATHOLOGY-RELATED PARAMETERS IN EXPLAINING THE VARIATION OF PUBLIC EXPENDITURES ON MEDICAL IMAGING
|
Puttevils, D
|
|
2002
|
5 |
6 |
p. 469-470
2 p.
|
artikel
|
| 203 |
PHP24 USE OF POLICY MODELING TO PROMOTE INFORMED DECISION MAKING: DEVELOPMENT AND APPLICATION OF THE CANADIAN STROKE POLICY MODEL
|
Matchar, DB
|
|
2002
|
5 |
6 |
p. 473-
1 p.
|
artikel
|
| 204 |
PHP2 VARIABILITY IN EUROPEAN REIMBURSEMENT SCHEMES FOR ANTIBIOTICS: CONSEQUENCES FOR EUROPEAN SURVEILLANCE OF ANTIBIOTIC CONSUMPTION (ESAC PROJECT)
|
Ferech, M
|
|
2002
|
5 |
6 |
p. 464-465
2 p.
|
artikel
|
| 205 |
PHP22 WEBSITES AS TOOLS OF PROMOTING HEALTH IN SOUTH EAST EUROPE
|
Tasic, Lj
|
|
2002
|
5 |
6 |
p. 472-
1 p.
|
artikel
|
| 206 |
PIN32 A COMPARISON OF CONJOINT ANALYSIS AND TIME TRADE OFF ELICITED UTILITIES FOR QUALITY OF LIFE STATES ASSOCIATED WITH THE TREATMENT OF GENITAL HERPES
|
Doward, LC
|
|
2002
|
5 |
6 |
p. 574-
1 p.
|
artikel
|
| 207 |
PIN37 A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER: POTENTIAL IMPACT OF AN HPV 16/18 VACCINE
|
Goldie, S
|
|
2002
|
5 |
6 |
p. 576-
1 p.
|
artikel
|
| 208 |
PIN11 COMPARING HOSPITAL COSTS BETWEEN LINEZOLID AND VANCOMYCIN IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCAL SPECIES (MRSS) INFECTIONS:A RANDOMIZED MULTI-CENTER CLINICAL TRIAL
|
Glick, HA
|
|
2002
|
5 |
6 |
p. 565-566
2 p.
|
artikel
|
| 209 |
PIN19 COST BENEFIT ANALYSIS ON VACCINATION FOR MEASLES IN JAPAN
|
Takahashi, K
|
|
2002
|
5 |
6 |
p. 568-569
2 p.
|
artikel
|
| 210 |
PIN14 COST-CONSEQUENCE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/r) VS. NELFINAVIR (NFV) THERAPY IN TREATING ANTIRETROVIRAL NAÏVE HIV PATIENTS USING CLINICAL TRIAL DATA
|
Luo, MP
|
|
2002
|
5 |
6 |
p. 566-567
2 p.
|
artikel
|
| 211 |
PIN6 COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS TEICOPLANIN IN THE TREATMENT OF INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA IN SPAIN
|
Grau, S
|
|
2002
|
5 |
6 |
p. 563-
1 p.
|
artikel
|
| 212 |
PIN5 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) FOR THE TREATMENT OF SEVERE SEPSIS:A CROSS-NATIONAL COMPARISON OF THREE EUROPEAN COUNTRIES
|
Neilson, A
|
|
2002
|
5 |
6 |
p. 563-
1 p.
|
artikel
|
| 213 |
PIN4 COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN
|
Sacristán, JA
|
|
2002
|
5 |
6 |
p. 562-
1 p.
|
artikel
|
| 214 |
PIN17 COST-EFFECTIVENESS OF 23-VALENT ANTIPNEUMOCOCCICAL VACCINATION IN CATALONIA (SPAIN)
|
Plans-Rubió, P
|
|
2002
|
5 |
6 |
p. 568-
1 p.
|
artikel
|
| 215 |
PIN15 ECONOMIC BURDEN OF CHRONIC HEPATITIS B VIRUS INFECTION AND POTENTIAL COST SAVINGS WITH LAMIVUDINE
|
Chen, X
|
|
2002
|
5 |
6 |
p. 567-
1 p.
|
artikel
|
| 216 |
PIN10 ECONOMIC EVALUATION DEMONSTRATES THAT MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE SPANISH NATIONAL HEALTHCARE SYSTEM WHEN COMPARED TO IV/PO AMOXICILLIN/CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
|
Drummond, M
|
|
2002
|
5 |
6 |
p. 565-
1 p.
|
artikel
|
| 217 |
PIN33 FACTORS INFLUENCING INAPPROPRIATE ANTIBIOTIC PRESCRIBING FOR CHILDREN WITH ACUTE BRONCHITIS IN AMBULATORY CARE SETTING
|
Koompalum, D
|
|
2002
|
5 |
6 |
p. 574-575
2 p.
|
artikel
|
| 218 |
PIN13 FIVE-YEAR BUDGET IMPACT AND LIFETIME COST EFFECTIVENESS OF A LOPINAVIR/RITONAVIR (LVP/r) VS.A NELFINAVIR (NFV) CONTAINING REGIMEN FOR TREATMENT-NAÏVE PATIENTS
|
Simpson, KN
|
|
2002
|
5 |
6 |
p. 566-
1 p.
|
artikel
|
| 219 |
PIN30 FURTHER DEVELOPMENT OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE
|
Doll, HA
|
|
2002
|
5 |
6 |
p. 573-
1 p.
|
artikel
|
| 220 |
PIN21 HOSPITALISATION COSTS FOR YOUNG CHILDREN WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION
|
Vergouwe, Y
|
|
2002
|
5 |
6 |
p. 569-570
2 p.
|
artikel
|
| 221 |
PIN24 IMPACT OF INFLUENZA VACCINATION ON WORK PRODUCTIVITY IN A COLOMBIAN COMPANY: COSTS AND BENEFITS FOR THE EMPLOYER
|
Tasset, A
|
|
2002
|
5 |
6 |
p. 570-571
2 p.
|
artikel
|
| 222 |
PIN27 IMPACT OF SIMPLER HIV-THERAPY ON ADHERENCE AND QUALITY OF LIFE
|
Arpinelli, F
|
|
2002
|
5 |
6 |
p. 572-
1 p.
|
artikel
|
| 223 |
PIN36 INCIDENCE OF SEVERE SEPSIS IN THE NETHERLANDS:A POINT PREVALENCE SURVEY
|
Van Gestel, A
|
|
2002
|
5 |
6 |
p. 576-
1 p.
|
artikel
|
| 224 |
PIN16 INFLUENZA TREATMENT WITH OSELTAMIVIR IN A HIGH RISK POPULATION—A COSTEFFECTIVE OPTION FOR THE HEALTH CARE PAYER
|
Sander, B
|
|
2002
|
5 |
6 |
p. 567-568
2 p.
|
artikel
|
| 225 |
PIN34 INITIAL ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C:A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYSIS
|
Siebert, U
|
|
2002
|
5 |
6 |
p. 575-
1 p.
|
artikel
|
| 226 |
PIN31 INVESTIGATION INTO THE FEASIBILITY OF DERIVING RELATIVE AND ABSOLUTE UTILITY FROM THE RECURRENT GENITAL HERPES QUALITY OF LIFE QUESTIONNAIRE (RGHQOL)
|
Doward, LC
|
|
2002
|
5 |
6 |
p. 573-574
2 p.
|
artikel
|
| 227 |
PIN8 LENGTH OF STAY AND ANTIFUNGAL TREATMENTS COSTS IN PATIENTS WITH SYSTEMIC MYCOSIS: DESCRIPTION AND ASSOCIATED FACTORS
|
Peiró, S
|
|
2002
|
5 |
6 |
p. 564-
1 p.
|
artikel
|
| 228 |
PIN7 OUTCOMES AND PATIENT CHARACTERISTICS ASSOCIATED WITH SYSTEMIC FUNGAL INFECTIONS
|
Santiago, JY
|
|
2002
|
5 |
6 |
p. 563-564
2 p.
|
artikel
|
| 229 |
PIN12 PHARMACOECONOMIC ANALYSIS OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS TREATMENT WITH TELITHROMYCIN OR CEFUROXIME-AXETIL
|
Rubio-Terrés, C
|
|
2002
|
5 |
6 |
p. 566-
1 p.
|
artikel
|
| 230 |
PIN9 PHARMACOECONOMIC ANALYSIS OF COMMUNITY ACQUIRED PNEUMONIA TREATMENT WITH TELITHROMYCIN OR CLARITHROMYCIN
|
Rubio-Terrés, C
|
|
2002
|
5 |
6 |
p. 564-565
2 p.
|
artikel
|
| 231 |
PIN23 PHARMACOECONOMIC EVALUATION OF ANTIBACTERIALS UTILIZATION IN PRIMARY, SECONDARY AND TERTIARY HOSPITALS IN DEVELOPING ECONOMY
|
Suleiman, IA
|
|
2002
|
5 |
6 |
p. 570-
1 p.
|
artikel
|
| 232 |
PIN22 PHARMACOECONOMIC EVALUATION OF STREPTOMYCIN VERSUS ETHAMBUTOL AS PRIMARY ANTITUBERCULAR DRUGS IN LAGOS UNIVERSITY TEACHING HOSPITAL
|
Suleiman, IA
|
|
2002
|
5 |
6 |
p. 570-
1 p.
|
artikel
|
| 233 |
PIN29 PSYCHOMETRIC PROPERTIES OF THE MODIFIED VIH-47 IN A THERAPEUTIC TRIAL EVALUATING THE IMPACT OF AN EDUCATIONAL PROGRAM IN HIV + PATIENTS
|
Arnould, B
|
|
2002
|
5 |
6 |
p. 573-
1 p.
|
artikel
|
| 234 |
PIN18 RELEVANCE OF COMPLICATIONS AS COST DRIVERS OF VARICELLA
|
Klose, T
|
|
2002
|
5 |
6 |
p. 568-
1 p.
|
artikel
|
| 235 |
PIN28 REVIEW OF QOL AND HRQOL INSTRUMENTS AVAILABLE FOR MEASURING OUTCOME IN HIV/AIDS
|
Meads, DM
|
|
2002
|
5 |
6 |
p. 572-
1 p.
|
artikel
|
| 236 |
PIN2 SEVERE SEPSIS: CLINICAL TRIAL VERSUS DAILY PRACTICE.A COST ANALYSIS IN BELGIUM
|
Laterre, PF
|
|
2002
|
5 |
6 |
p. 561-562
2 p.
|
artikel
|
| 237 |
PIN20 THE COST-EFFECTIVENESS OF ANTIRETROVIRAL REGIMENS CONTAINING PROTEASE INHIBITORS (PIS) OR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) IN THE TREATMENT OF HIV-INFACTED INDIVIDUALS IN POLAND
|
Kowalik, E
|
|
2002
|
5 |
6 |
p. 569-
1 p.
|
artikel
|
| 238 |
PIN26 THE COST EFFECTIVENESS OF SAFE AND APPROPRIATE USE OF INJECTION POLICIES IN HEALTH CARE SETTINGS
|
Dziekan, G
|
|
2002
|
5 |
6 |
p. 571-572
2 p.
|
artikel
|
| 239 |
PIN1 THE COSTS OF SEVERE SEPSIS—THE NETHERLANDS, 2000
|
Van Gestel, A
|
|
2002
|
5 |
6 |
p. 558-
1 p.
|
artikel
|
| 240 |
PIN3 THE TREATMENT OF SEPSIS PATIENTS WITH DROTRECOGIN ALFA (ACTIVATED):AN ECONOMIC EVALUATION WITH REFERENCE TO ITALY
|
Lucioni, C
|
|
2002
|
5 |
6 |
p. 562-
1 p.
|
artikel
|
| 241 |
PIN25 VACCINATION IN HEALTHY WORKING ADULTS:WHAT RETURN ON INVESTMENT FOR COMPANIES? AN INTERNATIONAL PERSPECTIVE
|
Anne, T
|
|
2002
|
5 |
6 |
p. 571-
1 p.
|
artikel
|
| 242 |
PIN35 VARICELLA VACCINATION OF PRE-SCHOOL CHILDREN: DETERMINING OPTIMAL COVERAGE LEVELS
|
Klose, T
|
|
2002
|
5 |
6 |
p. 575-576
2 p.
|
artikel
|
| 243 |
PMD19 A CRITICAL REVIEW OF HEALTH-RELATED PRODUCTIVITY MEASURES
|
Prasad, M
|
|
2002
|
5 |
6 |
p. 535-536
2 p.
|
artikel
|
| 244 |
PMD11 A DALY IS A QALY—OR IS IT?
|
Essink-Bot, ML
|
|
2002
|
5 |
6 |
p. 532-533
2 p.
|
artikel
|
| 245 |
PMD16 ASSESSING QUALITY OF LIFE IN THE ELDERLY: A COMPARISON OF TWO UTILITY MEASURES
|
Holland, R
|
|
2002
|
5 |
6 |
p. 534-
1 p.
|
artikel
|
| 246 |
PMD17 ASSESSMENT OF QUALITY OF LIFE IN CHILDREN: METHOLOGICAL AND CONCEPTUAL ISSUES
|
Matza, LS
|
|
2002
|
5 |
6 |
p. 535-
1 p.
|
artikel
|
| 247 |
PMD9 BEHAVIOURAL ECONOMICS:THE IMPORTANCE OF ABSOLUTE AND RELATIVE HEALTH OUTCOMES
|
Van Exel, J
|
|
2002
|
5 |
6 |
p. 532-
1 p.
|
artikel
|
| 248 |
PMD12 GENERIC VERSUS TREATMENT SPECIFIC TREATMENT SATISFACTION MEASUREMENT
|
Brod, M
|
|
2002
|
5 |
6 |
p. 533-
1 p.
|
artikel
|
| 249 |
PMD10 ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP TRANSLATION AND CULTURAL ADAPTATION: PROGRESS ON THE DEVELOPMENT OF PRINCIPLES OF BEST PRACTICE
|
Wild, DJ
|
|
2002
|
5 |
6 |
p. 532-
1 p.
|
artikel
|
| 250 |
PMD6 MODIFYING COST-EFFECTIVENESS RATIOS TO BE MAXIMALLY COMPARABLE ACROSS MULTIPLE DISEASES:AN APPLICATION OF MANIFOLD THEORY
|
Gold, K
|
|
2002
|
5 |
6 |
p. 530-531
2 p.
|
artikel
|
| 251 |
PMD3 RELEVANCE OF PATIENT REPORTED OUTCOMES FOR CHRONIC PAIN PATIENTS: THE ROLE OF SATISFACTION WITH ANALGESIC MEDICATION AND APPLICATION FORM
|
Anderson-Hillemacher, A
|
|
2002
|
5 |
6 |
p. 529-530
2 p.
|
artikel
|
| 252 |
PMD14 THE INFLUENCE OF ILLNESS EXPERIENCE ON HEALTH STATE VALUATIONS
|
Joore, MA
|
|
2002
|
5 |
6 |
p. 533-534
2 p.
|
artikel
|
| 253 |
PMD15 THE INFLUENCE OF ILLNESS EXPERIENCE ON VALUATION COMPRESSION
|
Joore, MA
|
|
2002
|
5 |
6 |
p. 534-
1 p.
|
artikel
|
| 254 |
PMD18 THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROGRAMME—WHQ AND PGWBI DATABASES: REFERENCES VALUES FOR CROSSCULTURAL COMPARISONS
|
Lobo-Luppi, L
|
|
2002
|
5 |
6 |
p. 535-
1 p.
|
artikel
|
| 255 |
PMD1 THE NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT AND ITS APPLICATION TO PHARMACOECONOMICS ANALYSIS
|
Aino, H
|
|
2002
|
5 |
6 |
p. 529-
1 p.
|
artikel
|
| 256 |
PMD13 THE RELEVANCE OF QUANTITY AND QUALITY OF LIFE-YEARS AFTER TREATMENT IN PRIORITIZING BETWEEN DIFFERENT PATIENTS
|
Arnold, SV
|
|
2002
|
5 |
6 |
p. 533-
1 p.
|
artikel
|
| 257 |
PMD2 THE USE OF DISCRETE CHOICE MODELLING IN THE DESIGN OF CLINICAL TRIALS
|
Backhouse, ME
|
|
2002
|
5 |
6 |
p. 529-
1 p.
|
artikel
|
| 258 |
PMD8 TRENDS IN DATA SOURCES USED FOR ECONOMIC EVALUATION
|
Boler, A
|
|
2002
|
5 |
6 |
p. 531-532
2 p.
|
artikel
|
| 259 |
PMD7 VALUATION OF INFORMAL CARE:THE OPPORTUNITY COST METHOD APPLIED IN CAREGIVING FOR STROKE AND RHEUMATOID ARTHRITIS PATIENTS
|
Van den Berg, B
|
|
2002
|
5 |
6 |
p. 531-
1 p.
|
artikel
|
| 260 |
PMD5 VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS
|
Cassimon, D
|
|
2002
|
5 |
6 |
p. 530-
1 p.
|
artikel
|
| 261 |
PMD4 WHEN CAN MISSING DATA BE CONSIDERED MISSING AT RANDOM (MAR) IN SUBSTANCE ABUSE TREATMENT OUTCOMES RESEARCH?
|
Ciesla, JR
|
|
2002
|
5 |
6 |
p. 530-
1 p.
|
artikel
|
| 262 |
PMH3 A COST-EFFECTIVENESS COMPARISON OF OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
|
Beard, S
|
|
2002
|
5 |
6 |
p. 515-
1 p.
|
artikel
|
| 263 |
PMH22 ADHD HAS A SIGNIFICANT BURDEN UPON THE INDIVIDUAL, FAMILY AND SOCIETY IN EUROPE
|
Ralston, SJ
|
|
2002
|
5 |
6 |
p. 522-523
2 p.
|
artikel
|
| 264 |
PMH5 A DISCRETE EVENTS MODEL OF LONG-TERM OUTCOMES AND COST OF TREATMENT WITH LONG ACTING RISPERIDONE IN SCHIZOPHRENIA
|
Heeg, BM
|
|
2002
|
5 |
6 |
p. 515-516
2 p.
|
artikel
|
| 265 |
PMH11 ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY
|
Eichmann, F
|
|
2002
|
5 |
6 |
p. 518-
1 p.
|
artikel
|
| 266 |
PMH2 ANTIPSYCHOTIC USE PATTERNS AND HEALTHCARE COSTS FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH HALOPERIDOL, OLANZAPINE OR RISPERIDONE IN A MEDICAID POPULATION
|
Ramsey, JL
|
|
2002
|
5 |
6 |
p. 514-
1 p.
|
artikel
|
| 267 |
PMH23 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD):A RECOGNISED DISORDER FOR CHILDREN IN EUROPE
|
Ralston, SR
|
|
2002
|
5 |
6 |
p. 523-
1 p.
|
artikel
|
| 268 |
PMH7 BOTTOM-UP OR TOP-DOWN? IMPACT OF PATIENT SELECTION ON COST-OF-ILLNESS RESULTS
|
van Asselt, ADI
|
|
2002
|
5 |
6 |
p. 516-
1 p.
|
artikel
|
| 269 |
PMH25 CORRESPONDENCE COURSE FOR GPS IMPROVED QUALITY AND PERSISTENCY OF ANTI-DEPRESSIVE THERAPY (RESULTS FROM THE IMPROVE-D STUDY)
|
Michalek, HE
|
|
2002
|
5 |
6 |
p. 524-
1 p.
|
artikel
|
| 270 |
PMH8 COST-EFFECTIVENESS OF MIRTAZAPINE COMPARED TO FLUOXETINE IN THE TREATMENT OF MODERATE AND SEVERE DEPRESSION IN HUNGARY
|
Van Loon, J
|
|
2002
|
5 |
6 |
p. 517-
1 p.
|
artikel
|
| 271 |
PMH6 DIRECT MEDICAL COSTS FOR TREATMENT OF PATIENTS EXPERIENCING BIPOLAR DISORDER EPISODES IN THE UK
|
Finnern, HW
|
|
2002
|
5 |
6 |
p. 516-
1 p.
|
artikel
|
| 272 |
PMH9 ESTIMATING COST-EFFECTIVENESS OF CONCERTA OROS IN ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)—ADAPTING THE CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT'S (CCOHTA) ECONOMIC MODEL OF METHYLPHENIDATE IMMEDIATE RELEASE VERSUS BEHAVIOURAL INTERVENTIONS FROM A PARENT'S PERSPECTIVE
|
Annemans, L
|
|
2002
|
5 |
6 |
p. 517-
1 p.
|
artikel
|
| 273 |
PMH4 ESTIMATING MEDICAL COST REDUCTION IN TREATING SCHIZOPHRENIA WITH CLOZAPINE
|
Sendersky, V
|
|
2002
|
5 |
6 |
p. 515-
1 p.
|
artikel
|
| 274 |
PMH18 EVALUATION OF CLINICAL EFFICACY OF WEEKLY FLUOXETIN COMPARED WITH DAILY FLUOXETIN 40 MG IN AMBULATORY PATIENTS WITH MAJOR DEPRESSION
|
Ortega, T
|
|
2002
|
5 |
6 |
p. 521-
1 p.
|
artikel
|
| 275 |
PMH19 GENDER DIFFERENCES IN PSYCHOACTIVE MEDICATION TREATMENT FOR ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (AD/HD): RESULTS FROM A POPULATION-BASED STUDY
|
Barbaresi, WJ
|
|
2002
|
5 |
6 |
p. 521-522
2 p.
|
artikel
|
| 276 |
PMH21 IMPROVING THE MEASUREMENT PROPERTIES OF THE QUALITY OF LIFE IN DEPRESSION SCALE
|
McKenna, SP
|
|
2002
|
5 |
6 |
p. 522-
1 p.
|
artikel
|
| 277 |
PMH14 INCIDENCE OF HYPERLIPIDEMIA DURING TREATMENT OF SCHIZOPHRENIA: FINDINGS IN A CLAIMS DATABASE
|
Zhao, Z
|
|
2002
|
5 |
6 |
p. 519-520
2 p.
|
artikel
|
| 278 |
PMH10 LENGTH OF STAY AND ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED TO HOSPITAL: DESCRIPTION AND ASSOCIATED FACTORS— THE PSYCHOSP STUDY
|
Peiró, S
|
|
2002
|
5 |
6 |
p. 518-
1 p.
|
artikel
|
| 279 |
PMH12 PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO OBSERVATIONAL STUDY
|
Eichmann, F
|
|
2002
|
5 |
6 |
p. 518-519
2 p.
|
artikel
|
| 280 |
PMH16 RECRUITMENT FOR SCHIZOPHRENIA RESEARCH: EXPLORING THE DIFFERENCES BETWEEN COMMUNITY MENTAL HEALTH CENTERS AND NATIONAL ALLIANCE FOR THE MENTALLY ILL
|
Mackell, J
|
|
2002
|
5 |
6 |
p. 520-
1 p.
|
artikel
|
| 281 |
PMH15 SEXUAL DYSFUNCTION AND ANTIPSYCHOTIC DRUG ADHERENCE IN PEOPLE WITH SCHIZOPHRENIA
|
Weiden, PJ
|
|
2002
|
5 |
6 |
p. 520-
1 p.
|
artikel
|
| 282 |
PMH26 SIMULATING THE COURSE OF SCHIZOPHRENIA USING DISCRETE EVENTS MODELLING
|
Heeg, BM
|
|
2002
|
5 |
6 |
p. 524-
1 p.
|
artikel
|
| 283 |
PMH13 STUDY DESCRIPTION AND BASELINE RESULTS OF THE SCHIZOPHRENIA OUTCOMES SURVEY (SOS) OBSERVATIONAL STUDY IN BELGIUM
|
Annemans, L
|
|
2002
|
5 |
6 |
p. 519-
1 p.
|
artikel
|
| 284 |
PMH20 THE EFFECTS OF ETHNICITY AND ANTIPSYCHOTIC AGENT ON MEDICATION ADHERENCE IN A MEDICAID POPULATION
|
Opolka, J
|
|
2002
|
5 |
6 |
p. 522-
1 p.
|
artikel
|
| 285 |
PMH1 THE HEALTH CARE COSTS OF SCHIZOPHRENIA IN AUSTRALIA: 18-MONTH FOLLOW-UP RESULTS
|
Christova, L
|
|
2002
|
5 |
6 |
p. 514-
1 p.
|
artikel
|
| 286 |
PMH24 THERE ARE SIGNIFICANT BARRIERS TO THE DIAGNOSIS AND TREATMENT OF ADHD IN EUROPE
|
Ralston, SJ
|
|
2002
|
5 |
6 |
p. 523-524
2 p.
|
artikel
|
| 287 |
PMH17 TREATMENT SATISFACTION AND COMPLIANCE WITH RISPERIDONE USE IN PATIENTS WITH BIPOLAR DISORDER
|
Bolge, SC
|
|
2002
|
5 |
6 |
p. 520-521
2 p.
|
artikel
|
| 288 |
PNP8 ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES:A LIFETIME COST-UTILITY ANALYSIS
|
Maltoni, S
|
|
2002
|
5 |
6 |
p. 509-510
2 p.
|
artikel
|
| 289 |
PNP1 CHOLINESTERASE INHIBITORS REDUCE INSTITUTIONALIZATION RISK AND MAY REDUCE OVERALL ECONOMIC BURDEN FOR PATIENTS WITH DEMENTIA IN A NATURALISTIC TREATMENT SETTING
|
Luong, D
|
|
2002
|
5 |
6 |
p. 507-
1 p.
|
artikel
|
| 290 |
PNP17 COMPLIANCE OF TWO TREATMENTS OF ALZHEIMER'S DISEASE
|
Barbeau, M
|
|
2002
|
5 |
6 |
p. 513-
1 p.
|
artikel
|
| 291 |
PNP5 DIRECT COSTS OF BACK PAIN IN THE UNITED STATES:A NATIONAL ESTIMATE
|
Mychaskiw, MA
|
|
2002
|
5 |
6 |
p. 508-509
2 p.
|
artikel
|
| 292 |
PNP7 ECONOMIC EVALUATION OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN REFRACTORY EPILEPTIC PATIENTS
|
Blais, L
|
|
2002
|
5 |
6 |
p. 509-
1 p.
|
artikel
|
| 293 |
PNP10 ECONOMIC IMPACT OF GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS
|
Ollendorf, DA
|
|
2002
|
5 |
6 |
p. 510-511
2 p.
|
artikel
|
| 294 |
PNP2 ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY—A PROGNOSIS TO 2050
|
Happich, MV
|
|
2002
|
5 |
6 |
p. 507-
1 p.
|
artikel
|
| 295 |
PNP15 EVALUATION OF THE RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY
|
Selai, C
|
|
2002
|
5 |
6 |
p. 512-513
2 p.
|
artikel
|
| 296 |
PNP18 FORMULARY DECISION SUPPORT FOR INTERFERON-BETA-1A USING ANALYSIS OF CARE-SEEKING BEHAVIOR FOR MULTIPLE SCLEROSIS
|
Meyer, C
|
|
2002
|
5 |
6 |
p. 513-514
2 p.
|
artikel
|
| 297 |
PNP16 MEDICATION USE IN PATIENTS WITH LOW BACK PAIN: DATA FROM MANAGED CARE
|
Harley, C
|
|
2002
|
5 |
6 |
p. 513-
1 p.
|
artikel
|
| 298 |
PNP12 PHYSICIAN PREFERENCE FOR ANTIEPILEPTIC DRUG CONCENTRATION TESTING
|
Baumann, RJ
|
|
2002
|
5 |
6 |
p. 511-
1 p.
|
artikel
|
| 299 |
PNP13 QUALITY OF LIFE (QOL) AND PHARMACOECONOMICAL ASPECTS IN PATIENTS WITH SYMPTOMATIC LOCALIZATION-RELATED EPILEPSIES (SLE) IN MOSCOW
|
Guekht, AB
|
|
2002
|
5 |
6 |
p. 511-512
2 p.
|
artikel
|
| 300 |
PNP9 RETROSPECTIVE EVALUATION OF DYSPORTTM AND BOTOXTM DRUG UTILIZATION IN THE MANAGEMENT OF PATIENTS WITH CERVICAL DYSTONIA OR BLEPHAROSPASM
|
Magar, R
|
|
2002
|
5 |
6 |
p. 510-
1 p.
|
artikel
|
| 301 |
PNP3 SOCIO-ECONOMIC IMPACT OF CHRONIC DAILY HEADACHE IN THE GENERAL POPULATION IN FRANCE
|
Lantéri-Minet, M
|
|
2002
|
5 |
6 |
p. 507-508
2 p.
|
artikel
|
| 302 |
PNP4 SWITCHING AND PERSISTENCY IN A NSAID AND COX-2 SPECIFIC INHIBITOR USER POPULATION IN MANAGED CARE
|
Harley, C
|
|
2002
|
5 |
6 |
p. 508-
1 p.
|
artikel
|
| 303 |
PNP6 THE BURDEN OF MIGRAINE: BEYOND DIRECT HEALTH CARE COSTS
|
Badia, X
|
|
2002
|
5 |
6 |
p. 509-
1 p.
|
artikel
|
| 304 |
PNP11 USE OF THE TOPS AS A PAIN-SPECIFIC HRQOL INSTRUMENT
|
Oderda, GM
|
|
2002
|
5 |
6 |
p. 511-
1 p.
|
artikel
|
| 305 |
POD1 AN ECONOMIC EVALUATION OF NOVOSEVEN IN THE MANAGEMENT OF HAEMOPHILIA PATIENTS WITH INHIBITORS IN SLOVAKIA
|
Hart, WM
|
|
2002
|
5 |
6 |
p. 576-577
2 p.
|
artikel
|
| 306 |
POD9 A PHARMACOECONOMIC EVALUATION OF THE USE OF THYROTROPIN-ALFA (THYROGEN®) IN THE DETECTION OF THYROID REMNANTS AND WELLDIFFERENTIATED THYROID CANCER IN THE DUTCH HEALTH CARE SETTING
|
de Peuter, MA
|
|
2002
|
5 |
6 |
p. 580-
1 p.
|
artikel
|
| 307 |
POD2 DEVELOPMENT OF ECONOMIC AND OUTCOMES MODEL OF HEMOPHILIA TREATMENT IN LATIN AMERICA AND SOUTH
|
Roberts, H
|
|
2002
|
5 |
6 |
p. 577-
1 p.
|
artikel
|
| 308 |
POD6 ELECTRONIC IMPLEMENTION OF AN APPROVED TABLET SPLITTING GUIDE WITH PROVIDER ORDER ENTRY—ASSOCIATED COST SAVINGS
|
Schaefer, MG
|
|
2002
|
5 |
6 |
p. 578-579
2 p.
|
artikel
|
| 309 |
POD5 EVALUATION OF A PALLIATIVE CARE TEAM ON RESOURCE UTILIZATION IN AN ACUTE CARE SETTING
|
Conner, T
|
|
2002
|
5 |
6 |
p. 578-
1 p.
|
artikel
|
| 310 |
POD10 IMPROVEMENT IN QUALITY OF LIFE IN GROWTH HORMONE (GH) REPLACED HYPOPITUITARY ADULTS WITH GH DEFICIENCY IS CORRELATED WITH PATIENTREPORTED OUTCOMES:ANALYSIS OF THE KIMS DATABASE
|
Koltowska-Häggström, M
|
|
2002
|
5 |
6 |
p. 580-
1 p.
|
artikel
|
| 311 |
POD4 INCIDENCE AND PREVENTION OF NEEDLE STICK INJURY RELATED TO SUBCUTANEOUS INJECTION: EXAMPLE OF THE IMPACT OF A LOW MOLECULAR WEIGHT HEPARIN SAFETY SYRINGE
|
Bouvet, E
|
|
2002
|
5 |
6 |
p. 578-
1 p.
|
artikel
|
| 312 |
POD3 JOINT RECOVERY IN HIP AND KNEE REPLACEMENT:A COST-EFFECTIVE APPROACH
|
Brunenberg, D
|
|
2002
|
5 |
6 |
p. 577-
1 p.
|
artikel
|
| 313 |
POD8 THE COST-EFFECTIVENESS OF OSTEOGENIC PROTEIN 1 IN THE TREATMENT OF TIBIAL NONUNIONS IN THE UK AND GERMANY
|
van Engen, AK
|
|
2002
|
5 |
6 |
p. 579-
1 p.
|
artikel
|
| 314 |
POD7 THE IMPACT OF FALLING ON HEALTH CARE UTILIZATION AND COSTS:A COMPARISON OF PROPENSITY SCORING AND TWO-PART MODELS
|
Rizzo, JA
|
|
2002
|
5 |
6 |
p. 579-
1 p.
|
artikel
|
| 315 |
PRK4 AN ECONOMIC MODEL OF UNSTABLE BLADDER IN BELGIUM
|
Kurth, H
|
|
2002
|
5 |
6 |
p. 582-
1 p.
|
artikel
|
| 316 |
PRK12 APPLYING CONJOINT ANALYSIS TO THE VALUATION OF OVERACTIVE BLADDER DRUGEFFICACY VARIABLES AND SIDE EFFECTS
|
Brown, MCJ
|
|
2002
|
5 |
6 |
p. 585-
1 p.
|
artikel
|
| 317 |
PRK1 ASSESSING PROVIDER TIME FOR ANAEMIA MANAGEMENT OF DIALYSIS PATIENTS USING TIME & MOTION METHODS:A MULTI-CENTRE OBSERVATIONAL STUDY IN EUROPE
|
De Cock, E
|
|
2002
|
5 |
6 |
p. 581-
1 p.
|
artikel
|
| 318 |
PRK5 A STRAIGHTFORWARD COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER: CAN IT BE THIS SIMPLE?
|
Noe, LL
|
|
2002
|
5 |
6 |
p. 582-583
2 p.
|
artikel
|
| 319 |
PRK15 A SURVEY ON THE CLINICAL MANAGEMENT OF CMV RISK IN PATIENTS FOLLOWING RENAL TRANSPANTATION IN FRANCE
|
Legendre, C
|
|
2002
|
5 |
6 |
p. 586-
1 p.
|
artikel
|
| 320 |
PRK11 BPH AND IPSS SCORES EVALUATED AFTER SIX MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 584-585
2 p.
|
artikel
|
| 321 |
PRK3 BRANDED VS GENERIC CYCLOSPORINE IN DE-NOVO KIDNEY TRANSPLANTATION—WHERE ARE THE COST SAVINGS?
|
Pirk, O
|
|
2002
|
5 |
6 |
p. 581-582
2 p.
|
artikel
|
| 322 |
PRK2 COSTS OF CHRONIC KIDNEY DISEASE (CKD): COST AND COMORBIDITY
|
Smith, DH
|
|
2002
|
5 |
6 |
p. 581-
1 p.
|
artikel
|
| 323 |
PRK6 EVALUATING THE COST OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER
|
Becker, RV
|
|
2002
|
5 |
6 |
p. 583-
1 p.
|
artikel
|
| 324 |
PRK8 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN CHRONIC DIALYSIS PATIENTS:A CRITICAL COMPARISON OF CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) AND CENTRE HEMODIALYSIS (CHD)
|
Procaccini, DA
|
|
2002
|
5 |
6 |
p. 583-584
2 p.
|
artikel
|
| 325 |
PRK7 PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE)
|
Marchetti, M
|
|
2002
|
5 |
6 |
p. 583-
1 p.
|
artikel
|
| 326 |
PRK9 PATIENTS TREATED WITH SERENOA REPENS: EVOLUTION OF THE IPSS SCORES IN TERMS OF IRRITATION AND OBSTRUCTION
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 584-
1 p.
|
artikel
|
| 327 |
PRK10 PATIENTS TREATED WITH SERENOA REPENS: EVOLUTION OF THE SCORES SPI AND SF12
|
Taöeb, C
|
|
2002
|
5 |
6 |
p. 584-
1 p.
|
artikel
|
| 328 |
PRK14 PREVALENCE OF APPROPRIATE URINARY INCONTINENCE EVALUATIONS IN TEXAS NURSING HOME FACILITIES
|
Monroe, DM
|
|
2002
|
5 |
6 |
p. 585-586
2 p.
|
artikel
|
| 329 |
PRK13 REGIONAL SIMILARITIES IN IMPROVEMENT AND PERSISTENCE OF SHORT-TERM HEALTH-RELATED QUALITY OF LIFE EFFECT OF TOLTERODINE ON OVERACTIVE BLADDER PATIENTS
|
Pleil, AM
|
|
2002
|
5 |
6 |
p. 585-
1 p.
|
artikel
|
| 330 |
PRP10 A DISEASE MANAGEMENT PROGRAM IN FRANCE: LESSONS FROM THE RESALIS EXPERIMENT 18 MONTHS BEFORE AND 12 MONTHS AFTER PUBLIC HEALTH INTERVENTIONS
|
Launois, R
|
|
2002
|
5 |
6 |
p. 528-
1 p.
|
artikel
|
| 331 |
PRP3 AN ANALYSIS OF THE LENGTH AND COSTS OF RESPIRATOR USE WITH OBSERVATIONAL DATA BASED ON MEDICAL RECORDS
|
Watanabe, R
|
|
2002
|
5 |
6 |
p. 525-
1 p.
|
artikel
|
| 332 |
PRP6 ASSESSMENT OF RESPIRATORY DISEASE SEVERITY USING POSTAL QUESTIONNAIRES
|
Hazell, ML
|
|
2002
|
5 |
6 |
p. 526-527
2 p.
|
artikel
|
| 333 |
PRP5 EPIDEMIOLOGICAL STUDY ESTIMATING THE PREVALENCE OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS IN GERMANY
|
Elies, W
|
|
2002
|
5 |
6 |
p. 526-
1 p.
|
artikel
|
| 334 |
PRP9 EVALUATION OF A DISEASE MANAGEMENT PROGRAM (DMP) FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY: PRELIMINARY ASSESSMENT OF EFFECTIVENESS OF COMPOUNDS
|
Lorenz, J
|
|
2002
|
5 |
6 |
p. 528-
1 p.
|
artikel
|
| 335 |
PRP7 HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ASTHMA PATIENTS IN RELATIONSHIP TO ASTHMA SEVERITY DEGREE
|
Rebollo, P
|
|
2002
|
5 |
6 |
p. 527-
1 p.
|
artikel
|
| 336 |
PRP4 INHALED ANTIINFLAMMATORY MEDICATION USE AND SUBSEQUENT HOSPITALIZATIONS AMONG TEXAS MEDICAID PATIENTS WITH PERSISTENT ASTHMA
|
Smith, M
|
|
2002
|
5 |
6 |
p. 526-
1 p.
|
artikel
|
| 337 |
PRP1 INPATIENT AND OBSERVATION UNIT COSTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
O'Brien, JA
|
|
2002
|
5 |
6 |
p. 525-
1 p.
|
artikel
|
| 338 |
PRP8 QUALITY OF LIFE AND COSTS FOR MODERATE AND SEVERE ASTHMA IN FRANCE
|
Lafuma, A
|
|
2002
|
5 |
6 |
p. 527-
1 p.
|
artikel
|
| 339 |
PRP2 3329 STUDY TO EVALUATE HOSPITAL COSTS FOR ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN (EPOC-COST STUDY)
|
García, A
|
|
2002
|
5 |
6 |
p. 525-
1 p.
|
artikel
|
| 340 |
PWM9 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND FETAL MALFORMATIONS
|
de vries, LE
|
|
2002
|
5 |
6 |
p. 590-
1 p.
|
artikel
|
| 341 |
PWM8 ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND SPONTANEOUS ABORTIONS
|
Logman, JFS
|
|
2002
|
5 |
6 |
p. 589-
1 p.
|
artikel
|
| 342 |
PWM2 COST ANALYSIS OF IVF TREATMENT WITH INJECTION DEVICE VS THE TRADITIONAL SYRINGE AND NEEDLE
|
Johannes, E
|
|
2002
|
5 |
6 |
p. 587-
1 p.
|
artikel
|
| 343 |
PWM1 HEALTH CARE RESOURCE USE FOR HEAVY MENSTRUAL LOSS
|
Jacobs, P
|
|
2002
|
5 |
6 |
p. 586-587
2 p.
|
artikel
|
| 344 |
PWM4 INFLUENCE OF ERECTILE DYSFUNCTION ON HEALTH RELATED QUALITY OF LIFE OF MALE KIDNEY TRANSPLANT PATIENTS ACCORDING TO AGE
|
Rebollo, P
|
|
2002
|
5 |
6 |
p. 587-588
2 p.
|
artikel
|
| 345 |
PWM6 POST-MENOPAUSAL HORMONE THERAPY: DO HYPERTENSION AND THROMBOPHILIA MATTER?
|
Marchetti, M
|
|
2002
|
5 |
6 |
p. 588-589
2 p.
|
artikel
|
| 346 |
PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION
|
Torrance, G
|
|
2002
|
5 |
6 |
p. 588-
1 p.
|
artikel
|
| 347 |
PWM3 SECOND-GENERATION VERSUS FIRSTGENERATION ENDOMETRIAL ABLATION TECHNIQUES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB):A REVIEW OF THE LITERATURE
|
Lessard, C
|
|
2002
|
5 |
6 |
p. 587-
1 p.
|
artikel
|
| 348 |
PWM7 USING A DISCRETE CHOICE EXPERIMENT TO VALUE AN INJECTION DEVICE FOR INFERTILITY TREATMENT
|
Brown, RE
|
|
2002
|
5 |
6 |
p. 589-
1 p.
|
artikel
|
| 349 |
PWM10 VITAMIN USE AMONG WOMEN OF CHILDBEARING AGE IN US: EVIDENCE FROM THE 1997 MEPS DATA
|
DeVeaugh-Geiss, A
|
|
2002
|
5 |
6 |
p. 590-
1 p.
|
artikel
|
| 350 |
Subject Index, Volume 5
|
|
|
2002
|
5 |
6 |
p. 607-609
3 p.
|
artikel
|
| 351 |
UT5 COMPARISON OF THE SF6D AND THE EQ5D IN PATIENTS REQUIRING CORONARY REVASCULARISATION
|
van Stel, HF
|
|
2002
|
5 |
6 |
p. 461-
1 p.
|
artikel
|
| 352 |
UT3 ESTIMATING HEALTH UTILITY FROM A PHYSICAL FUNCTION ASSESSMENT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7)
|
Boggs, R
|
|
2002
|
5 |
6 |
p. 452-453
2 p.
|
artikel
|
| 353 |
UT6 IMPROVEMENT IN HEALTH UTILITY AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7), A FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY
|
van de Putte, L
|
|
2002
|
5 |
6 |
p. 461-
1 p.
|
artikel
|
| 354 |
UT1 36 INTO 1 DOESN'T GO
|
Kind, P
|
|
2002
|
5 |
6 |
p. 452-
1 p.
|
artikel
|
| 355 |
UT4 PATIENT-DERIVED UTILITY ESTMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES
|
Greiner, W
|
|
2002
|
5 |
6 |
p. 460-461
2 p.
|
artikel
|
| 356 |
UT2 THE TRANSFORMATION OF SOCIAL PREFERENCE WEIGHTS: IMPLICATIONS FOR COST-EFFECTIVENESS
|
Cleemput, I
|
|
2002
|
5 |
6 |
p. 452-
1 p.
|
artikel
|
| 357 |
WD1 NHP AND 15D PERFORM WELL IN ASSESSMENT OF THE HRQOL OF HEALTHY WOMEN WITH HORMONE REPLACEMENT THERAPY
|
Sintonen, H
|
|
2002
|
5 |
6 |
p. 447-
1 p.
|
artikel
|
| 358 |
WD3 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY IN FIVE EUROPEAN COUNTRIES FOR HUMALOG MIX25 COMPARED TO HUMULIN 30/70 FOR THE TREATMENT OF TYPE 2 DIABETES
|
Aristides, M
|
|
2002
|
5 |
6 |
p. 448-
1 p.
|
artikel
|
| 359 |
WD2 PRE-TERM PREGNANCY TERMINATIONS FOLLOWING EXPOSURE TO ANTIDEPRESSANTS:A META-ANALYSIS
|
Hemels, MEH
|
|
2002
|
5 |
6 |
p. 447-
1 p.
|
artikel
|
| 360 |
WP2 ESTIMATING WILLINGNESS TO PAY FOR DRUGS TO TREAT ADHD—A CONTINGENT VALUATION STUDY IN STUDENTS
|
De Ridder, A
|
|
2002
|
5 |
6 |
p. 462-
1 p.
|
artikel
|
| 361 |
WP3 WILLINGNESS TO PAY FOR A PHARMACIST INTERVENTION PROGRAM AMONG NONCOMPLIANT DYSLIPIDEMIA PATIENTS
|
Ali, F
|
|
2002
|
5 |
6 |
p. 462-463
2 p.
|
artikel
|
| 362 |
WP1 WILLINGNESS TO PAY FOR PHARMACISTPROVIDED MENOPAUSE AND HORMONE REPLACEMENT THERAPY CONSULTATIONS
|
Branvold, AE
|
|
2002
|
5 |
6 |
p. 462-
1 p.
|
artikel
|
Tijdschrift beschrijving